Jubbonti

Jubbonti Overdosage

denosumab

Manufacturer:

Novartis Pharmaceutical Manufacturing GmbH

Distributor:

Marketer:

Sandoz

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Warnings Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Caution For Usage Storage Patient Counseling Information MIMS Class ATC Classification Thai FDA Category Presentation/Packing

Full Prescribing Info

Overdosage

There is no experience with overdose in clinical studies. Denosumab has been administered in clinical studies using doses up to 180 mg every 4 weeks (cumulative doses up to 1,080 mg over 6 months), and no additional adverse reactions were observed.

Continue with Google

Already a member? Sign In